C2 PHARMA Expands Advisory Board to Support Growth Objectives
Luxembourg, March 3, 2020 – C2 PHARMA (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, has expanded their advisory board with a new member. Consisting of well-respected pharmaceutical industry experts, the board provides strategic guidance on the progress and growth of the company via organic and M&A activities in the mid and long-term.
“The C2 PHARMA advisory board now includes Jim Miller, who joins existing members Dr. Uwe H. Böhlke, Joachim Roeser, and Dr. Jürgen Sackhoff,” Andrew Badrot, CEO of C2 PHARMA said. “We are thrilled to expand our advisory board and align to gain their insight as we grow into a premier ophthalmic and niche active pharmaceutical ingredient (API) supplier with a unique virtual manufacturing model. The prowess each member brings to the board is invaluable in creating sustainable growth, while making a clear mark on this industry.”
Jim Miller founded PharmSource, a pioneering online database for contract manufacturing intelligence now run by Global Data. He is regarded as a biopharmaceutical contract manufacturing and development sector expert and is a frequent contributor to industry publications and events, as well as working as a consultant and a member of the Board of Advisors of C2 PHARMA.
Dr. Uwe H. Böhlke is a leading executive manager and board member for companies across the chemicals, pharmaceuticals and polymers industries. Today, he is the chief operating officer (COO) at REHAU. A former member of the executive board at Lonza, and Oerlikon Surface Solutions AG, he is since 2014 a member of the Board of Advisors of C2 PHARMA.
Joachim Roeser has vast experience in business development and executive management for the chemicals, material science and polymers industries. Formerly, he held CEO and president positions for Amber Chemical Group, Luzenac and Ferro Group. Today he is the board director for Innospec Inc., in addition to his role as a member of the Board of Advisors of C2 PHARMA.
Dr. Jürgen Sackhoff is a distinguished professional with a diverse executive and legal background. He spent more than 3 years as CEO at SGD Pharma, with a history of 14 years at Schott AG ending as Executive Vice President of Pharmaceutical Systems, and nearly a decade of General Counsel and legal work with Henkel Corporation and Generali. In 2018, he branched into independent executive consultation, legal and board work, including joining as a member of the Board of Advisors of C2 PHARMA.
The announcement follows a recent expansion of the company’s API product portfolio with successful validation of Homatropine Hydrobromide and additions to the Digoxin API offering. Further R&D development and tech transfers are in process and will be announced in 2020.
About C2 PHARMA
Established in 2014, C2 PHARMA is a Luxembourg-based manufacturer and distributor of active pharmaceutical ingredients (APls) from phytochemical and chemical origins. The company focuses on developing APIs that are niche, complex, difficult to manufacture, challenging to sell or to transport by combining best-in-class manufacturing, quality oversight and technical expertise. The current API product portfolio includes atropine, digoxin, homatropine, pilocarpine and more than 20 APIs are at various stages of R&D development. Customized GDP cold-chain logistics solutions are offered through a specialized affiliate: Logistics4Pharma. R&D-scale contract synthesis services, analytical services, phytochemical profiling and impurities manufacturing are provided via its affiliate ASM Research Chemicals.
tel: +352 28 26 11 00
White Matter Communications
tel: +1 415 905 0324